Teva's Weltruza Seen as Launch-Execution Story After Clean Label, Oppenheimer Says
MT newswire2026/10/09 16:5212:52 PM EDT, 10/09/2026 (MT Newswires) -- Teva Pharmaceutical Industries' (TEVA) Weltruza approval removes the label risk that defined the long-acting olanzapine debate, leaving launch execution as the key question, Oppenheimer said in a note Friday. With no REMS, no post-injection observation requirement and no boxed warning for post-injection delirium sedation syndrome, Weltruza is the first practical olanzapine LAI, the firm said. Oppenheimer expects a quiet first half of 2027 focused on sampling, hospital formularies and state-by-state Medicaid additions, with meaningful revenue in the second half. It said the launch should be judged on samples, formulary wins and prescriptions, not early sales. The $3,950 monthly list price, 47% above Oppenheimer's initial assumption, signals Teva's confidence in the profile, the firm said. It assumes a 40% gross-to-net discount and flagged rebate depth as the key variable through 2027. Oppenheimer raised its price target to $52 from $50 and reiterated its outperform rating. Price: 41.64, Change: +2.39, Percent Change: +6.08
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
